<DOC>
	<DOCNO>NCT01883999</DOCNO>
	<brief_summary>The Iliac Branch Endoprosthesis ( IBE ) 12-04 study prospective , nonrandomized , multicenter , single-arm evaluation design assess safety efficacy IBE Device subject common iliac artery aneurysm ( CIAA ) aorto-iliac aneurysm ( AIA ) .</brief_summary>
	<brief_title>Evaluation GORE® EXCLUDER® Iliac Branch Endoprosthesis</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Iliac Aneurysm</mesh_term>
	<criteria>1 . Common iliac aneurysm without concomitant abdominal aortic aneurysm 2 . Adequate native anatomy receive EXCLUDER® Iliac Branch Endoprostheses 3 . An Informed Consent Form sign Subject legally authorize representative 4 . Male infertile female 5 . Able comply protocol requirement include followingup 6 . Life expectancy &gt; 2 year 7 . Age &gt; 21 year 8 . Surgical candidate 1 . Mycotic rupture aneurysm 2 . Known concomitant thoracic aortic aneurysm require intervention 3 . American Society Anesthesiologists ( ASA ) Physical Status classification system class V ( moribund patient expect live 24 hour without operation ) 4 . Renal insufficiency define patient undergoing dialysis 5 . New York Heart Association ( NYHA ) Functional Classification class IV 6 . Dissected , heavily calcify , heavily thrombose land zone ( ) 7 . Tortuous stenotic iliac and/or femoral artery 8 . Participating another investigational device drug study within 1 year treatment 9 . Systemic infection may increase risk endovascular graft infection 10 . Known degenerative connective tissue disease , e.g. , Marfan EhlerDanlos Syndrome 11 . Planned concomitant surgical procedure major surgery within 30 day treatment date 12 . Known history drug abuse 13 . Known sensitivity allergy device material</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>